Tag: Biotechnology Research

Slingshot Biosciences
United States

Tiffany Salas-Morris Joins Slingshot Biosciences as Chief Commercial Officer

Press Release – November 06, 2024 – EMERYVILLE, Calif. – Slingshot Biosciences, Inc. (Slingshot Biosciences), a leading biotechnology company revolutionizing the development of cell mimics for diagnostic and therapeutic applications, is excited to announce the appointment of Tiffany Salas-Morris as Chief Commercial Officer (CCO). In her new role, Tiffany will lead the company’s commercial strategy, focusing on accelerating growth, expanding market presence, and driving customer … Continue reading Tiffany Salas-Morris Joins Slingshot Biosciences as Chief Commercial Officer

Impact Newswire
Myrobalan Therapeutics
United States

Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer

Dr. Kleiman brings more than 25 years of neuroscience drug discovery leadership, including the discovery and development of multiple novel clinical candidates Press Releae – October 31, 2024 – MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announces the appointment of Robin Kleiman, Ph.D., as … Continue reading Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer

Impact Newswire
Cellino
United States

Cellino Appoints Chris Gibson to Board of Directors

CAMBRIDGE, Mass. – Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. “The intersection of deep technology, biology, and medicine presents unprecedented opportunities and challenges. We are thrilled to have Chris’ experience on our board to provide Cellino with a perspective that is both visionary and deeply … Continue reading Cellino Appoints Chris Gibson to Board of Directors

Impact Newswire
enGene
United States

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

October 21, 2024 – BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of … Continue reading enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Impact Newswire
Vianautis
Untied Kingdom

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who has been stepping down from her role. Dr Adi Hoess brings a wealth of experience to ViaNautis, having previously served as CEO of Nasdaq-listed German … Continue reading ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

Impact Newswire
axolbio
Europe

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, October 2024: Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell … Continue reading Axol Bioscience acquires Phenocell to advance human disease models

Impact Newswire
Seaport Therapeutics
United States

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 … Continue reading Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Impact Newswire
Judo Bio
United States

Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

STRIKE platform to deliver siRNA and other genetic medicines to the kidney for the treatment of systemic diseases and renal diseases Lead pipeline programs use megalin receptors for intracellular delivery of ligand-siRNA conjugates to specific kidney cells to target and silence genes, including solute carrier proteins CAMBRIDGE, Mass., October 7, 2024 — Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced … Continue reading Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

Impact Newswire